In truth, it is a huge combination of factors, including pharmaceutical costs (but still nowhere near the greatest cost factor, especially if you consider the effect of biosimilars savings over the past 5 years), provider charges (which are ALWAYS highly variable across the country), payer inefficiency, PBM profiteering, and inappropriate utilization, and others (like low-value treatments, too many MRIs and robotic surgery suites, to name a few)
One Class B plus two Class C Q9
By targeting healing where it actually happens, at the cellular level, BPC-157 promotes faster recovery and improved tissue function
By protecting the fragile glutathione molecule in a phospholipid shell, liposomal delivery overcomes the hurdles of the digestive system and delivers nutrients where they matter most: inside your cells